Browse News

Found 1,322 articles

• The Caris Precision Oncology Alliance Welcomes University of Chicago Medicine Comprehensive Cancer Center

  3/8/2023

  Caris Life Sciences announced today that the University of Chicago (UChicago) Medicine Comprehensive Cancer Center has joined the Caris Precision Oncology Alliance™ (POA).

• Caris Life Sciences and Incyte Enter Into Broad Precision Medicine Partnership to Advance Incyte's Oncology Pipeline

  3/7/2023

  Caris Life Sciences today announced a strategic research partnership with Incyte Corporation (NASDAQ:INCY) to augment precision medicine approaches for Incyte's oncology pipeline.

• Recludix Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference

  3/7/2023

  Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present an overview of the company at the virtual Oppenheimer 33rd Annual Healthcare Conference.

• COGNANO, Inc.: Statistical Discovery of Triple-negative Breast Cancer-specific Antibodies From a Huge Database Obtained by Alpaca Immunization

  3/1/2023

  COGNANO, Inc. and associates announced the discovery of a panel of antibodies specific for triple-negative breast cancer.

• Blueprint Medicines Presents Registrational Data from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting

  2/26/2023

  Blueprint Medicines Corporation announced detailed results from the PIONEER trial of AYVAKIT® in patients with indolent systemic mastocytosis.

• Blueprint Medicines to Regain Global Rights to GAVRETO® (pralsetinib) from Roche

  2/23/2023

  Blueprint Medicines Corporation (NASDAQ: BPMC) today announced it will regain global commercialization and development rights to GAVRETO® (pralsetinib), excluding Greater China , following a decision by Roche to discontinue the collaboration agreement between the companies for GAVRETO for strategic reasons.

• First Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European Commission

  2/20/2023

  Global biotechnology leader CSL (ASX: CSL) today announced that the European Commission has granted conditional marketing authorization (CMA) for HEMGENIX® (etranacogene dezaparvovec), the first and only one-time gene therapy for the treatment of severe and moderately severe hemophilia B (congenital Factor IX deficiency) in adults without a history of Factor IX inhibitors.

• Blueprint Medicines Reports Fourth Quarter and Full Year 2022 Results

  2/16/2023

  Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2022.

• Caris Life Sciences to Showcase Research with Leading Cancer Centers at ASCO Genitourinary Cancers Symposium 2023 Reflecting Its Commitment to Improving Outcomes for Patients

  2/13/2023

  Caris Life Sciences® announced that the company and partners within the Caris Precision Oncology Alliance™ will collectively present five studies across three tumor types at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium, February 16-18, 2023 in San Francisco.

• Jubilant Therapeutics Inc. receives Orphan Drug Designation for the PRMT5 inhibitor - JBI-778 for the treatment of Glioblastoma Multiforme (GBM)

  2/13/2023

  Jubilant Therapeutics Inc., a clinical stage biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced that the United States Food and Drug Administration (US FDA) has granted Orphan Drug Designation (ODD) for JBI-778 for the treatment of Glioblastoma Multiforme (GBM).

• Blueprint Medicines Announces Partial Clinical Hold for Phase 1/2 VELA Trial of BLU-222

  2/10/2023

  Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) verbally informed the company on February 8, 2023 that it has placed a partial clinical hold on the Phase 1/2 VELA trial of BLU-222 due to visual adverse events (AEs) observed in a limited number of patients.

• Baxter Reports Fourth-Quarter and Full-Year 2022 Results

  2/9/2023

  Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2022, and provided its financial guidance for full-year and first-quarter 2023.

• Ipsen presents strong full-year 2022 results and guidance for 2023

  2/9/2023

  Ipsen, a global specialty-driven biopharmaceutical company, presents its financial results for the year and the fourth quarter of 2022.

• Blueprint Medicines to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023

  2/9/2023

  Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 16, 2023 to report its fourth quarter and full year 2022 financial results and provide a corporate update.

• MOMA Therapeutics Appoints Industry Leader Jeff Albers as Chair of the Board of Directors

  2/8/2023

  MOMA Therapeutics today announced the appointment of Jeff Albers as independent chairperson of the company’s board of directors.

• Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 07, 2023

  2/7/2023

  Blueprint Medicines Corporation announced that, effective February 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 36,260 shares of its common stock and an aggregate of 18,119 restricted stock units to 24 new employees under Blueprint Medicines' 2020 Inducement Plan.

• Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs

  2/3/2023

  Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases, announces that research from a real-world study of netupitant or fosnetupitant with palonosetron (NEPA) has been published in the journal Future Oncology.

• Blueprint Medicines to Present Positive Data from PIONEER Trial of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting

  2/3/2023

  Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present detailed results from the registrational PIONEER trial of AYVAKIT® (avapritinib) in indolent systemic mastocytosis (SM) at the 2023 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting, February 24 to 27 in San Antonio.

• Recludix Pharma to Present at the Guggenheim Healthcare Talks Oncology Conference

  2/1/2023

  Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present an overview of the company at the Guggenheim Healthcare Talks Oncology Conference in New York, NY.

• ReLive Biotechnologies, Ltd. Completes Asset Purchase of Co.Don AG and Series A Financing Led By SHC, Furthering its Ambition to Become the Global Leader in Regenerative Therapies

  1/26/2023

  ReLive Biotechnologies, Ltd., taking over the global patent rights of its flagship products "Spherox" and "Chondrosphere".